Calithera Biosciences, Inc. (NASDAQ:CALA) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.
Other equities research analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $19.00 price objective (up from $14.00) on shares of Calithera Biosciences in a research note on Monday, June 12th. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, May 12th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $20.00 price objective (up from $15.00) on shares of Calithera Biosciences in a research note on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Calithera Biosciences currently has a consensus rating of “Hold” and a consensus target price of $15.50.
Calithera Biosciences (CALA) traded up 0.36% during trading on Friday, hitting $14.00. 158,068 shares of the stock were exchanged. Calithera Biosciences has a one year low of $2.20 and a one year high of $20.05. The stock’s 50 day moving average is $15.77 and its 200-day moving average is $13.00. The company’s market cap is $496.66 million.
Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.14. The company had revenue of $7.26 million for the quarter, compared to the consensus estimate of $4.80 million. On average, equities research analysts expect that Calithera Biosciences will post ($0.83) earnings per share for the current fiscal year.
In other Calithera Biosciences news, VP Keith Orford sold 2,120 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $18.31, for a total value of $38,817.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 16.30% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of CALA. Cubist Systematic Strategies LLC boosted its stake in shares of Calithera Biosciences by 10.9% in the second quarter. Cubist Systematic Strategies LLC now owns 14,972 shares of the biotechnology company’s stock valued at $222,000 after buying an additional 1,472 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Calithera Biosciences by 17.5% in the first quarter. Bank of New York Mellon Corp now owns 32,688 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 4,863 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Calithera Biosciences by 68.1% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 17,000 shares of the biotechnology company’s stock valued at $252,000 after buying an additional 6,885 shares during the period. Legal & General Group Plc acquired a new stake in shares of Calithera Biosciences during the second quarter valued at approximately $120,000. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in shares of Calithera Biosciences by 49.2% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 27,600 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 9,100 shares during the period. Hedge funds and other institutional investors own 55.11% of the company’s stock.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
What are top analysts saying about Calithera Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Calithera Biosciences Inc. and related companies.